P Erben
Overview
Explore the profile of P Erben including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
463
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nientiedt M, Muller K, Nitschke K, Erben P, Steidler A, Porubsky S, et al.
J Cancer Res Clin Oncol
. 2020 Sep;
147(1):129-138.
PMID: 32951068
Purpose: To investigate the mRNA expression of B-MYB and MDM2 together with their p53 relatedness in clear cell renal cell carcinoma (ccRCC). Methods: Genes were screened for their mRNA expression...
2.
Wessels F, Kriegmair M, Oehme A, Rassweiler-Seyfried M, Erben P, Oberneder R, et al.
Eur J Surg Oncol
. 2019 Mar;
45(7):1260-1265.
PMID: 30827801
Introduction: Aim of this study was to analyse the perioperative outcome of patients undergoing radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid. Materials And Methods: Using prospectively maintained databases...
3.
Nitschke K, Erben P, Waldbillig F, Abdelhadi A, Weis C, Gottschalt M, et al.
World J Urol
. 2019 Feb;
38(3):637-645.
PMID: 30701334
Purpose: Fatty acid-binding protein 5 (FABP5), a transport protein for lipophilic molecules, has been proposed as protein marker in prostate cancer (PCa). The role of FABP5 gene expression is merely...
4.
Kriegmair M, Wirtz R, Worst T, Breyer J, Ritter M, Keck B, et al.
Transl Oncol
. 2018 Feb;
11(2):467-476.
PMID: 29477637
Introduction: Gene expression analyses have identified similarities between bladder and breast cancer, where clinical risk stratification is based on Her2, ESR1, PGR and Ki67 expression. The aim of the study...
5.
Worst T, Daskalova K, Steidler A, Berner-Leischner K, Roth R, Niesler B, et al.
World J Urol
. 2017 Jun;
35(11):1701-1711.
PMID: 28634911
Purpose: Until recently, tissue fibrosis-ultimately leading to permanent scaring-has been considered an irreversible process. However, recent findings indicate that it may be reversible after all. Vesicourethral anastomotic stenosis (VUAS) as...
6.
Erben P, Hartmann A, Bolenz C
Aktuelle Urol
. 2015 Jun;
46(3):227-35.
PMID: 26077307
Urothelial bladder cancer is characterised by high recurrence and progression rates despite multimodal treatment. Only slight improvements have been achieved during the last decades. The current histopathological classification and clinical...
7.
Martini T, Strobel P, Steidler A, Petrakopoulou N, Erben P, Bolenz C
Urologe A
. 2014 Nov;
54(1):70-5.
PMID: 25391439
Background: Lymphovascular invasion (LVI) represents a surrogate marker for micrometastatic urothelial carcinoma of the bladder (UCB). Objectives: We evaluated whether D2-40 immunhistochemistry (IHC) alters detection of LVI when compared to...
8.
Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, et al.
Leukemia
. 2014 May;
28(10):1988-92.
PMID: 24798484
Unlabelled: Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative...
9.
Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Fabarius A, et al.
Leukemia
. 2014 Jan;
28(7):1478-85.
PMID: 24472814
In the face of competing tyrosine kinase inhibitors (TKIs), identification of chronic myeloid leukemia (CML) patients expecting favorable response to second-line treatment is warranted. At the time of imatinib resistance,...
10.
Philipp M, Schwaab J, Dietz C, Hanfstein B, Kalmanti L, Munjal U, et al.
J Cancer Res Clin Oncol
. 2014 Jan;
140(3):411-7.
PMID: 24390277
Purpose: Overexpression of transketolase-like gene 1 (TKTL1) on RNA and protein level has been linked to tumour progression, metastasis and unfavourable patient outcome in many solid tumours. Chronic myeloid leukaemia...